Noticias y eventos de InMed Pharmaceuticals Inc (INM)INMInMed Pharmaceuticals Inc

InMed Pharmaceuticals Shareholders' Equity Falls Below Nasdaq Minimum Requirement

InMed Pharmaceuticals announces that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market, notifying the company that the shareholders' equity of $1.075M as reported in the company's annual report on Form 10-K for the fiscal year ended June 30, 2026, was below the minimum shareholders' equity of $2.5M required for continued listing on The Nasdaq Capital Market. The decline in the company's shareholders' equity is attributable largely to transaction-related expenses accrued in connection with the company's previously announced agreement and plan of merger and reorganization dated May 19, entered into with Mentari Therapeutics, pursuant to which, among other things, the company will merge with Mentari.

InMed Pharmaceuticals Amends Merger Agreement with Mentari

InMed Pharmaceuticals announced that it has entered into an amendment to the previously announced definitive merger agreement for an all-stock transaction with Mentari Therapeutics, a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp., a wholly-owned subsidiary of InMed, and Indigo Merger Sub II, LLC, a wholly-owned subsidiary of InMed. InMed also announced that it has filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission containing a preliminary proxy statement/prospectus and management information circular in connection with the proposed merger and related transactions contemplated by the Agreement. The Amendment, among other things, clarifies the sequencing of the Contemplated Transactions, reflects clarifications regarding the impact of the pre-closing financing on the exchange ratio, and clarifies the intended tax treatment of the Merger. Except as specifically modified by the Amendment, the Agreement remains in full force and effect. The Merger has received approval by the Boards of Directors of InMed and Mentari and is expected to close in the fourth quarter of 2026, subject to certain closing conditions, including, among others, approval by the shareholders of InMed and the stockholders of Mentari, the effectiveness of the S-4, and the satisfaction of other customary closing conditions. InMed filed on July 2, 2026 the S-4 containing a preliminary proxy statement/prospectus and management information circular with the SEC in connection with the Merger. The S-4 outlines the strategic rationale and merits of the Merger, as well as the processes undertaken by InMed and Mentari and their respective Boards of Directors in reaching their recommendations. While the S-4 has not yet become effective and the information contained therein is subject to change, it provides important information about the Contemplated Transactions. Once declared effective by the SEC, a date for a special meeting for InMed shareholders to approve the proposals associated with the transaction will be set, and the definitive proxy statement/prospectus and management information circular will be mailed to InMed shareholders prior to the vote.